Schonfeld G, Tikkanen M J, Hahm K S
Adv Exp Med Biol. 1985;183:135-57. doi: 10.1007/978-1-4613-2459-1_12.
In order to probe the structure and function of apoB, monoclonal antibodies directed against human LDL were produced. The seven antibodies tested were found to be directed against five individual antigenic determinants of apoB in holo-LDL. One of the antibodies inhibited the binding of 125I-LDL to the apoB, E receptor of cultured human fibroblasts. Limited proteolysis of LDL results in the production of relatively stable lipoprotein "core" particles that retain many physical, chemical and immunological properties of the native lipoprotein. Perturbations of the structure of apoB by limited proteolysis of LDL had selective effects on the expression of various epitopes in the resulting LDL "cores" - the expression of some was unaffected, others were abolished. In addition, the various epitopes could be localized by immunoblotting to different proteolytic fragments of apoB present in the LDL "cores". Limited proteolysis also provided water soluble cleavage peptides, some of which exhibited immunoreactivity. Digested LDL "core" particles and cleavage peptides both interacted with the LDL receptors of cultured human fibroblasts. These experiments suggest that apoB may consist of repeating subunits of similar structure. The immunoreactivity of LDL may be determined not only by the structure of the protein moiety itself, but also by other lipoprotein constituents. Studies utilizing both polyclonal and monoclonal anti-apoB antibodies have shown that apoB reacts differently in different types of lipoprotein particles (i.e., VLDL, IDL and LDL). We studied the immunological reactivities of apoB within the LDL class. The results showed that the expression of epitopes in different LDL preparations indeed varied, and that the number of epitopes expressed, appeared to be influenced by the lipid composition of LDL.
为了探究载脂蛋白B(apoB)的结构与功能,制备了针对人低密度脂蛋白(LDL)的单克隆抗体。所检测的七种抗体被发现针对全LDL中apoB的五个独立抗原决定簇。其中一种抗体抑制了125I-LDL与培养的人成纤维细胞的apoB、E受体的结合。LDL的有限蛋白酶解产生相对稳定的脂蛋白“核心”颗粒,这些颗粒保留了天然脂蛋白的许多物理、化学和免疫特性。通过LDL的有限蛋白酶解对apoB结构的扰动对所得LDL“核心”中各种表位的表达具有选择性影响——一些表位的表达不受影响,另一些则被消除。此外,各种表位可通过免疫印迹定位到LDL“核心”中存在的apoB的不同蛋白水解片段。有限蛋白酶解还提供了水溶性裂解肽,其中一些表现出免疫反应性。消化后的LDL“核心”颗粒和裂解肽都与培养的人成纤维细胞的LDL受体相互作用。这些实验表明apoB可能由结构相似的重复亚基组成。LDL的免疫反应性可能不仅由蛋白质部分本身的结构决定,还由其他脂蛋白成分决定。利用多克隆和单克隆抗apoB抗体的研究表明,apoB在不同类型的脂蛋白颗粒(即极低密度脂蛋白、中间密度脂蛋白和低密度脂蛋白)中的反应不同。我们研究了LDL类别中apoB的免疫反应性。结果表明,不同LDL制剂中表位的表达确实有所不同,并且表达的表位数量似乎受LDL脂质组成的影响。